Association of multimorbidity and changes in health-related quality of life following myocardial infarction: a UK multicentre longitudinal patient-reported outcomes study

Table 3 Adjusted parameter estimates from multilevel modelling of EQ-VAS scores and multi-morbidity classes, regression coefficient, and 95% confidence intervals

Variable	Regression coefficient (95% CI)	P value
Intercept	48.39 (40.06 to 56.72)
Month, baseline (ref)
1 month	4.62 (4.04 to 5.19)	<0.001*
6 months	3.43 (2.11 to 4.75)	<0.001*
12 months	−1.10 (−3.55 to 1.35)	0.38
Multimorbidity classes Mild (ref)
Moderate	−0.98 (−1.93 to −0.04)	0.04
Severe	−5.12 (−7.04 to −3.19)	<0.001*
Diagnosis(STEMI) ref
Diagnosis (NSTEMI)	−0.26 (−1.19 to 0.65)	0.57
Age	0.12 (0.08 to 0.15)	<0.001*
Women	−4.17 (−5.02 to −3.32)	<0.001*
Ethnicity White	0.81 (−1.61 to 3.24	0.51
Ex/current smoking status	−1.07 (−1.84 to -0.30)	0.01
Previous MI	−1.37 (−2.64 to −0.10)	0.03
Previous Angina	−2.15 (−3.27 to −1.04)	<0.001*
Treatments
Previous PCI	−1.53 (−2.96 to 0.11)	0.035
Previous CABG surgery	−3.03 (−4.64 to −1.42)	<0.001*

Adjusting for age, sex, ethnicity (white versus other) smoking status (never vs ex or current), past medical history of MI, angina, diagnosis (STEMI or NSTEMI), revascularisation (percutaneous coronary intervention [PCI] vs. no PCI; coronary artery bypass graft [CABG] surgery vs no CABG surgery), medications (B-blockers, statins, ACE, aspirin), cardiac rehabilitation (yes/no), and interactions of time and multimorbidity. Note: CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, MI myocardial infarction, STEMI ST-elevation myocardial infarction, NSTEMI non-ST-elevation myocardial infarction, ^*Significant after Hochberg correction using a false discovery rate of 0.05

ISSN: 1741-7015